Dr. Gilles Pagès works at the Institute for Research on Cancer and Aging of Nice (IRCAN), Centre Antoine Lacassagne, CNRS, INSERM, University Cote d’Azur (UCA). Dr. Pagès’s research interests mainly focus on the mechanisms of resistance to targeted therapies, especially anti-angiogenic drugs used for the treatment of several cancers, mainly kidney cancers and neovascular age-related macular degeneration. Dr Gilles Pagès also has strong expertise in cell signalling pathways, cell differentiation, cancer cell lines, cell cycle kinase inhibitors, pediatric brain cancer, medulloblastoma, targeted therapy, angiogenesis, and paediatric medulloblastoma. His scientific output includes 198 publications, corresponding to 18,617 citations (h-index 63) (Scopus, 15 December 2023). He participated in three clinical trials. He is the Honorary President of the French Society of Angiogenesis and a previous member of the European Vascular Biology Organization council. GP was elected member of the INSERM National Committee on Cancer (CSS2) and is a member of the INSERM Scientific Council. He is Honorary President of the French Society of Angiogenesis, which he chaired, and was a member of the Board of the European Organization of Vascular Biology. He cofounded Roca Therapeutics and Kekkan Biologics to implement the discoveries of his team in the clinic. His scientific output includes 198 publications, corresponding to 18,617 citations (h-index 63) (Scopus, 15 December 2023).